among
myriad
infecti
diseas
threat
human
face
bacteria
prion
parasit
protozoa
fungi
ectoparasit
virus
viral
infect
arguabl
constitut
biggest
pandem
threat
modern
era
replic
rate
transmiss
virus
two
major
factor
underli
threat
howev
least
one
addit
factor
play
essenti
role
lack
broadspectrum
antivir
agent
inde
bacteria
still
caus
substanti
epidem
part
world
access
clean
water
andor
antimicrobi
limit
pandem
threat
pose
bacteria
plaguecaus
yersinia
pesti
substanti
diminish
antibiot
era
virus
pose
epidem
risk
hand
current
therapeut
option
limit
virus
oblig
parasit
natur
must
use
host
cell
machineri
mani
function
thu
antivir
strategi
must
direct
viru
specif
care
avoid
interf
host
cellular
function
number
clear
target
per
viru
may
limit
contrast
bacteri
protein
synthesi
exampl
occur
via
ribosom
belong
bacteria
dispar
enough
human
ribosom
ident
specif
antibiot
deploy
target
bacteri
protein
synthesi
uniqu
featur
virus
deriv
natur
serv
delimit
antivir
therapi
manner
applic
antibacteri
therapi
addit
characterist
virus
serv
obstacl
broadspectrum
antivir
agent
includ
differ
rna
dna
virus
vastli
differ
viral
encod
protein
across
viral
famili
singl
doubl
strand
genom
structur
cytoplasm
nuclear
replic
cycl
degre
relianc
host
protein
exist
armamentarium
antivir
drug
rapidli
expand
cover
sever
viral
famili
howev
exist
antivir
agent
spectrum
activ
even
slightli
measur
spectrum
penicillin
sulfa
first
antibacteri
agent
discov
antivir
agent
current
avail
use
best
thought
highlytarget
specif
viru
case
member
viral
famili
current
trend
antivir
drug
develop
reflect
larg
effort
develop
exquisit
target
countermeasur
specif
virus
trend
exemplifi
monoclon
antibodi
rnai
compound
exampl
antivir
acyclovir
valacyclovir
famciclovir
util
variou
herp
famili
virus
herp
simplex
viru
varicellazost
viru
vzv
extent
broadspectrum
natur
even
carri
fellow
herp
viru
cytomegaloviru
cmv
acylovir
valacyclovir
famciclovir
nucleosid
analog
depend
viral
encod
thymidin
kinas
enzym
activ
separ
specif
target
antivir
ganciclovir
valganciclovir
foscarnet
letermovir
last
exquisit
target
cmv
use
treatment
prophylaxi
cmv
tenuou
natur
rudimentari
claim
broadspectrum
antivir
activ
also
evid
acyclovir
drop
activ
hzv
compar
fellow
viral
famili
member
despit
target
enzymat
function
thymidin
kinas
similarli
antihiv
medic
sever
class
primarili
target
antiretrovir
drug
class
nonnucleosid
revers
transcriptas
inhibitor
nnrti
certain
proteas
inhibitor
fusion
inhibitor
enfuvirtid
lack
efficaci
even
note
howev
nucleo
side
revers
transcriptas
inhibitor
lamivudin
emtricitabin
tenofovir
activ
outsid
hiv
competit
substrat
inhibitor
dna
synthesi
also
abl
inhibit
revers
transcriptas
enzym
encod
hepat
b
viru
hbv
like
due
share
evolutionari
origin
hbv
retrovirus
except
nucleo
side
revers
transcriptas
inhibitor
antihiv
medic
extens
group
antivir
avail
highli
specif
hiv
viral
protein
revers
transciptas
proteas
integras
maraviroc
hostsid
hiv
antivir
target
cellular
coreceptor
exclus
use
one
group
hiv
virus
tropic
hepat
c
proteas
inhibitor
simeprevir
quintessenti
target
agent
mani
activ
specif
genotyp
eg
simeprevir
hcv
let
alon
virus
mani
hcv
polymeras
inhibitor
inhibitor
similarli
constrain
spectrum
activ
specif
hcv
viral
protein
encod
specif
genotyp
exampl
ledipasivir
activ
genotyp
though
pangenotyp
combin
regimen
develop
howev
alway
specter
new
hcv
genotyp
evolv
may
less
suscept
agent
influenza
antivir
avail
us
also
highli
target
adamantan
amantadin
rimantadin
class
antivir
effect
influenza
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
effect
influenza
b
endonucleas
inhibitor
baloxavir
howev
given
target
protein
specif
influenza
virus
broadspectrum
natur
antisens
cmv
antivir
fomivirsen
monoclon
antibodi
target
rsv
fusion
protein
palivizumab
hostdirect
monoclon
antibodi
target
hiv
receptor
ibalizumab
design
intend
specif
smallpox
antivir
tecovirimat
inhibit
highli
conserv
envelop
protein
orthopox
virus
vital
tool
larg
orthopoxviru
famili
includ
emerg
reemerg
virus
sum
antivir
design
aim
block
function
one
specif
crucial
viral
protein
like
uniqu
specif
viru
viral
famili
drug
nucleo
side
revers
transcriptas
inhibitor
cross
viral
famili
due
homolog
protein
happen
exist
anoth
viral
famili
antivir
therapi
target
narrow
viral
rang
antivir
compound
characterist
qualifi
broadspectrum
natur
exampl
influenza
rna
depend
rna
polymeras
inhibitor
favipiravir
avail
japan
exhibit
broad
spectrum
rna
viru
activ
efficaci
polymeras
ebola
lassa
fever
activ
favipiravir
highlight
potenti
target
protein
univers
rna
virus
cidofovir
nucleotid
analog
spectrum
activ
consid
somewhat
broad
activ
dna
virus
includ
herp
polyoma
adeno
pox
viral
famili
less
toxic
deriv
remain
develop
brincidofovir
shown
vitro
activ
outsid
dna
virus
use
treatment
rnagenom
filoviru
ebola
human
efficaci
note
unclear
vitro
find
result
cell
toxic
vs
true
antivir
effect
ribavirin
nucleosid
analog
inhibit
viral
polymeras
enzym
also
might
character
broad
spectrum
activ
rna
virus
rsv
hepat
c
influenza
b
parainfluenza
virus
hepat
e
metapneumoviru
crimeancongo
hemorrhag
fever
cchf
new
oldworld
hemorrhag
arenavirus
eg
lassa
fever
junin
also
use
unsuccess
outbreak
rna
coronaviru
sar
dna
virus
adenovirus
also
inhibit
ribavirin
antivir
mechan
may
viral
famili
could
also
includ
immun
modul
also
seriou
toxic
concern
ribavirin
may
indic
cost
incur
broadspectrum
antivir
agent
import
note
nucleo
side
analog
cidofovir
ribavirin
along
hiv
nucleto
side
analog
mechan
action
focus
nucleic
acid
synthesi
may
larger
breadth
activ
possibl
greater
toxic
host
howev
highli
target
specif
seen
hepat
b
antivir
telbivudin
despit
part
class
antivir
develop
nucleosid
analog
remdesivir
shown
effect
filovirus
coronavirus
host
immunomodulatori
compound
interferon
imiquimod
conceptu
thought
broad
spectrum
howev
target
viru
directli
augment
intrins
antivir
activ
possess
immun
system
host
mani
antivir
initi
develop
singl
agent
target
compound
possibl
exist
repurpos
exist
antivir
agent
target
might
possibl
ganciclovir
valganciclovir
oral
ester
form
convert
ganciclovir
oral
administr
primarili
use
cmv
also
exhibit
abil
inhibit
two
dna
virus
vitro
adenoviru
hepat
b
viru
tenofovir
addit
activ
hiv
hbv
activ
dna
polymeras
hsv
foscarnet
pyrophosph
analog
block
pyrophosph
bind
site
viral
polymeras
primarili
consid
antivir
exclus
use
resist
herpesviru
infect
also
demonstr
activ
versu
revers
transcriptas
rna
depend
dna
polymeras
antihiv
activ
also
possess
hbv
revers
transcriptas
inhibitor
adefovir
entecavir
adefovir
also
possess
activ
dnapossess
poxvirus
herpesvirus
hiv
proteas
inhibitor
lopinavir
given
combin
ritonavir
repurpos
use
treatment
coronavirus
sar
mer
possess
proteas
though
clinic
efficaci
shown
date
antivir
agent
idoxuridin
trifluridin
topic
ophthalm
nucleosid
analog
antivir
exhibit
activ
hsv
dna
virus
vaccinia
adenoviru
interestingli
antiparasit
antibacteri
medic
nitazoxanid
shown
antivir
activ
distinct
mechan
hepat
b
hepat
c
noroviru
rotaviru
dengu
hiv
yellow
fever
japanes
enceph
influenza
pauciti
true
broadspectrum
antivir
agent
leav
major
chasm
prepared
viral
infecti
diseas
emerg
current
antivir
discoveri
process
strategi
driven
overarch
aim
find
treatment
specif
individu
virus
concern
viral
famili
let
alon
larger
group
virus
akin
gramposit
gramneg
spectrum
antibacteri
agent
fact
coupl
inher
uniqu
challeng
viral
class
pathogen
make
broad
spectrum
antivir
agent
develop
difficult
howev
mani
antivir
agent
might
amen
repurpos
favipiravir
ribavirin
cidofovir
brincidofovir
alreadi
shown
broadspectrum
properti
task
imposs
end
program
test
current
commerci
avail
shelf
antivir
offtarget
virus
pursu
process
occur
current
part
respons
west
africa
ebola
outbreak
larg
perform
postvir
emerg
preemptiv
part
initi
antivir
develop
antivir
develop
specif
target
also
systemat
assess
broadspectrum
antivir
activ
lastli
identifi
target
common
distinct
viral
famili
genet
similar
would
also
great
use
antivir
drug
develop
broadspectrum
strategi
pursu
complement
lieu
pursuit
target
therapi
monoclon
antibodi
also
hold
great
promis
treat
specif
viral
infect
evidenc
success
deploy
monoclon
antibodi
product
ebola
hendra
nipah
hope
futur
success
hiv
influenza
emphas
howev
may
need
balanc
broadspectrum
activ
toxic
host
mention
nucleo
ide
analog
toxic
lack
broadspectrum
antivir
agent
function
fact
virus
employ
host
cell
machineri
great
amount
activ
given
context
import
encourag
develop
monoclon
antibodi
immunemodul
well
viral
famili
specif
antivir
emerg
infecti
diseas
pandem
strike
bacteri
fungal
origin
could
almost
assur
clinician
microbiologist
pharmacologist
could
craft
effect
regimen
amongst
exist
antimicrobi
exact
phenomenon
occur
emerg
candida
auri
carbapenemresist
enterobacteriacea
cre
multidrug
resist
neisseria
gonorrhea
contrast
nearli
everi
novel
viral
epidem
region
global
import
character
common
refrain
support
care
mainstay
therapi
drug
trial
come
part
postoutbreak
antimicrobi
r
strategi
fund
take
account
place
high
prioriti
develop
broadspectrum
antivir
